These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1061 related items for PubMed ID: 25777187

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.
    J Acquir Immune Defic Syndr; 2014 Mar 01; 65(3):318-26. PubMed ID: 24525469
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.
    AIDS Patient Care STDS; 2014 Apr 01; 28(4):168-75. PubMed ID: 24660840
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
    White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD.
    Antivir Ther; 2015 Apr 01; 20(3):317-27. PubMed ID: 25321623
    [Abstract] [Full Text] [Related]

  • 10. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):855-865. PubMed ID: 27999048
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
    Porter DP, Daeumer M, Thielen A, Chang S, Martin R, Cohen C, Miller MD, White KL.
    Viruses; 2015 Dec 07; 7(12):6360-70. PubMed ID: 26690199
    [Abstract] [Full Text] [Related]

  • 14. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J, Moreno Guillén S, Antinori A, Yeni P, Wade B, Johnson M, Shalit P, Ebrahimi R, Johnson B, Walker I, De-Oertel S.
    Patient; 2015 Jun 07; 8(3):257-67. PubMed ID: 25808940
    [Abstract] [Full Text] [Related]

  • 15. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF, AI266073 Study Group.
    AIDS Patient Care STDS; 2010 Feb 07; 24(2):87-96. PubMed ID: 20156091
    [Abstract] [Full Text] [Related]

  • 16. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
    Gagliardini R, Bandera A, Zaccarelli M, Sterrantino G, Latini A, D'Avino A, Lapadula G, Antinori A, Cauda R, De Luca A, Gori A, Di Giambenedetto S, Fabbiani M.
    Antivir Ther; 2018 Feb 07; 23(2):139-148. PubMed ID: 28799920
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
    Sculier D, Gayet-Ageron A, Battegay M, Cavassini M, Fehr J, Hirzel C, Schmid P, Bernasconi E, Calmy A, Swiss HIV Cohort Study.
    BMC Infect Dis; 2017 Jul 06; 17(1):476. PubMed ID: 28683720
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.